These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31700973)

  • 21. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
    Li L; Chen X; He Z; Zhao X; Huang L; Yang D
    J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women.
    Sanke S; Chander R; Jain A; Garg T; Yadav P
    JAMA Dermatol; 2016 Sep; 152(9):986-91. PubMed ID: 27304785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermatologic manifestations of polycystic ovary syndrome.
    Lee AT; Zane LT
    Am J Clin Dermatol; 2007; 8(4):201-19. PubMed ID: 17645376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Obesity, hormonal and metabolic abnormalities in adolescent girls with polycystic ovary syndrome].
    Ságodi L; Lombay B; Vámosi I; Barkai L
    Orv Hetil; 2013 Aug; 154(31):1226-34. PubMed ID: 23895991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex hormone binding globulin gene polymorphisms and metabolic syndrome in postmenopausal Turkish women.
    Sunbul M; Eren F; Nacar C; Agirbasli M
    Cardiol J; 2013; 20(3):287-93. PubMed ID: 23788303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome.
    Chang AY; Lalia AZ; Jenkins GD; Dutta T; Carter RE; Singh RJ; Nair KS
    Metabolism; 2017 Jun; 71():52-63. PubMed ID: 28521878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperandrogenemia association with acne and hirsutism severity in Croatian women with polycystic ovary syndrome.
    Pavičić Baldani D; Škrgatić L; Bukvić Mokos Z; Trgovčić I
    Acta Dermatovenerol Croat; 2013; 21(2):105-12. PubMed ID: 24001418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex hormones and acne.
    Ju Q; Tao T; Hu T; Karadağ AS; Al-Khuzaei S; Chen W
    Clin Dermatol; 2017; 35(2):130-137. PubMed ID: 28274349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome).
    Melibary YT
    Dermatol Reports; 2018 Apr; 10(1):7546. PubMed ID: 29991979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study.
    Dalamaga M; Papadavid E; Basios G; Vaggopoulos V; Rigopoulos D; Kassanos D; Trakakis E
    J Am Acad Dermatol; 2013 Dec; 69(6):922-30. PubMed ID: 24120563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin resistance and skin diseases.
    Napolitano M; Megna M; Monfrecola G
    ScientificWorldJournal; 2015; 2015():479354. PubMed ID: 25977937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic syndrome in dermatology: Treatment and Management for Dermatologists.
    Engin B; Özkoca D; Kutlubay Z; Serdaroğlu S
    Dermatol Ther; 2019 Mar; 32(2):e12812. PubMed ID: 30620081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acromegaly with polycystic ovaries, hyperandrogenism, hirsutism, insulin resistance and acanthosis nigricans: a case report.
    Unal A; Sahin Y; Keleştimur F
    Endocr J; 1993 Apr; 40(2):207-11. PubMed ID: 7951506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acne severity and the Global Acne Grading System in polycystic ovary syndrome.
    Hacivelioglu S; Gungor AN; Gencer M; Uysal A; Hizli D; Koc E; Cosar E
    Int J Gynaecol Obstet; 2013 Oct; 123(1):33-6. PubMed ID: 23948280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
    Bhattacharya SM; Ghosh M; Basu R
    J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.
    Apridonidze T; Essah PA; Iuorno MJ; Nestler JE
    J Clin Endocrinol Metab; 2005 Apr; 90(4):1929-35. PubMed ID: 15623819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study.
    Keen MA; Shah IH; Sheikh G
    Indian Dermatol Online J; 2017; 8(2):104-110. PubMed ID: 28405549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hidradenitis suppurativa and the metabolic syndrome.
    Ergun T
    Clin Dermatol; 2018; 36(1):41-47. PubMed ID: 29241751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.